JP2017538672A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538672A5 JP2017538672A5 JP2017522532A JP2017522532A JP2017538672A5 JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5 JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017522532 A JP2017522532 A JP 2017522532A JP 2017538672 A5 JP2017538672 A5 JP 2017538672A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cmv
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 239000000427 antigen Substances 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 10
- 235000001014 amino acid Nutrition 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 101710132601 Capsid protein Proteins 0.000 claims 4
- 101710094648 Coat protein Proteins 0.000 claims 4
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 4
- 101710125418 Major capsid protein Proteins 0.000 claims 4
- 101710141454 Nucleoprotein Proteins 0.000 claims 4
- 101710083689 Probable capsid protein Proteins 0.000 claims 4
- 210000004897 n-terminal region Anatomy 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 239000013566 allergen Substances 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 241000223960 Plasmodium falciparum Species 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012434 Dermatitis allergic Diseases 0.000 claims 1
- 102100023688 Eotaxin Human genes 0.000 claims 1
- 101710139422 Eotaxin Proteins 0.000 claims 1
- 241000282324 Felis Species 0.000 claims 1
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
- 101900330356 Influenza A virus Matrix protein 2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000009053 Neurodermatitis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 claims 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14189897.3 | 2014-10-22 | ||
| EP14189897 | 2014-10-22 | ||
| EP15184192 | 2015-09-08 | ||
| EP15184192.1 | 2015-09-08 | ||
| PCT/EP2015/074269 WO2016062720A1 (en) | 2014-10-22 | 2015-10-20 | Modified virus-like particles of cmv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538672A JP2017538672A (ja) | 2017-12-28 |
| JP2017538672A5 true JP2017538672A5 (cg-RX-API-DMAC7.html) | 2018-11-22 |
| JP6942313B2 JP6942313B2 (ja) | 2021-09-29 |
Family
ID=54337283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017522532A Active JP6942313B2 (ja) | 2014-10-22 | 2015-10-20 | Ｃｍｖ由来改変ウイルス様粒子 |
Country Status (20)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| WO2017179025A1 (en) | 2016-04-15 | 2017-10-19 | Alk-Abelló A/S | Epitope polypeptides of ragweed pollen allergens |
| US10946078B2 (en) * | 2016-04-27 | 2021-03-16 | Benchmark Animal Health Ltd. | Treatment of canine atopic dermatitis |
| EP3448418A1 (en) | 2016-04-27 | 2019-03-06 | Allergy Therapeutics (UK) Limited | Treatment of peanut allergy |
| AU2018231413B2 (en) * | 2017-03-07 | 2024-01-04 | Evax Ag | Treatment of pruritus in horses |
| JP7250032B2 (ja) * | 2017-12-11 | 2023-03-31 | ユービーアイ アイピー ホールディングス | アトピー性皮膚炎の治療及び／または予防のためのｉｌ－３１のペプチド免疫原ならびにその製剤 |
| MA52011A (fr) * | 2018-03-16 | 2021-01-20 | Zoetis Services Llc | Vaccins peptidiques contre l'interleukine-31 |
| PE20201344A1 (es) | 2018-04-10 | 2020-11-25 | Ac Immune Sa | Vacunas terapeuticas anti-abeta |
| US20210205425A1 (en) | 2018-05-28 | 2021-07-08 | Evax Ag | Treatment of urticaria |
| US20220073946A1 (en) * | 2018-12-20 | 2022-03-10 | Saiba AG | Virus-like particles of cmv modified by fusion |
| EP3906316A4 (en) * | 2018-12-31 | 2022-11-30 | United Neuroscience Limited | PEPTIDE IMMUNOGENS FOR TARGETING CALCITONINGEN-RELATED PEPTIDE (CGRP) AND FORMULATIONS THEREOF FOR THE PREVENTION AND TREATMENT OF MIGRAINE |
| WO2021083766A1 (en) | 2019-10-29 | 2021-05-06 | Evax Ag | Treatment of pruritus in horses |
| US20230038487A1 (en) * | 2019-11-25 | 2023-02-09 | The Regents Of The University Of California | Modified viral therapeutics and uses thereof |
| WO2021260131A1 (en) | 2020-06-25 | 2021-12-30 | Saiba AG | Virus-like particles of cmv modified by fusion |
| CA3201533A1 (en) * | 2020-11-11 | 2022-05-19 | European Molecular Biology Laboratory | Modified viral particles for gene therapy |
| CA3199586A1 (en) * | 2020-11-23 | 2022-05-27 | Samantha J. Busfield | Antigen-binding molecules and uses thereof |
| CN112724204B (zh) * | 2020-12-15 | 2023-12-19 | 深圳赫兹生命科学技术有限公司 | 一种用于生产vlp重组疫苗的cmv病毒样颗粒及其制备方法 |
| CA3248669A1 (en) | 2022-01-19 | 2023-07-27 | Universitat Bern | COMPOSITIONS OF VIRUS-TYPE PARTICLES AND MICROCRYSTALLINE TYROSINE |
| CN114437211B (zh) * | 2022-01-26 | 2024-03-12 | 南京麦西崴克生物科技有限公司 | 基于猫过敏原Fel d1的卵黄抗体的制备方法 |
| CN119053345A (zh) | 2022-02-28 | 2024-11-29 | 特瑞德姆生物科技有限责任两合公司 | 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物 |
| CA3243636A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | CONJUGATED COMPRISING AT LEAST ONE β-GLUCANE OR ONE MANNANA |
| KR20250057809A (ko) | 2022-08-30 | 2025-04-29 | 사이바 애니멀 헬스 아게 | Cmv의 변형된 바이러스-유사 입자 |
| CN118684781A (zh) * | 2023-03-21 | 2024-09-24 | 深圳赫兹生命科学技术有限公司 | GnRH-VLP重组去势疫苗及其制备方法 |
| GB202400747D0 (en) * | 2024-01-19 | 2024-03-06 | Univ Dundee | IL31-VLP and medical uses thereof |
| TW202536171A (zh) | 2024-03-04 | 2025-09-16 | 德商百靈佳殷格翰獸藥股份有限公司 | 用於治療ｎｇｆ相關病症之主動疫苗接種 |
| WO2025186318A2 (en) | 2024-03-06 | 2025-09-12 | Elanco Us Inc. | Veterinary compositions of modified virus-like particles of cmv and feline il-1beta mutein antigens |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| WO1999066950A1 (en) * | 1998-06-20 | 1999-12-29 | United Biomedical Inc. | Synthetic somatostatin immunogen for growth promotion in farm animals |
| EP1278542A2 (en) * | 2000-05-05 | 2003-01-29 | Cytos Biotechnology AG | Molecular antigen arrays and vaccines |
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| RU2319503C2 (ru) | 2001-11-07 | 2008-03-20 | Цитос Байотекнолоджи Аг | Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний |
| DK1443960T3 (da) | 2001-11-07 | 2009-03-23 | Cytos Biotechnology Ag | Antigen-arrays der betegner IL-5, IL-13 eller eotaxin til behandling af allergiske eosinofile sygdomme |
| ATE521367T1 (de) | 2002-06-07 | 2011-09-15 | Kentucky Bioproc Llc | Flexlibler aufbau- und darreichungs-plattform von impfstoffen |
| GB0228715D0 (en) | 2002-12-09 | 2003-01-15 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2005091753A2 (en) | 2004-03-25 | 2005-10-06 | Large Scale Biology Corporation | Flexible vaccine assembly and vaccine delivery platform |
| NZ554387A (en) * | 2004-09-21 | 2009-09-25 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of AP205 and an antigenic polypeptide |
| AU2006214325B2 (en) * | 2005-02-14 | 2012-04-05 | National Jewish Medical And Research Center | Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells |
| US7767212B2 (en) * | 2005-03-18 | 2010-08-03 | Cytos Biotechnology Ag | CAT allergen conjugates and uses thereof |
| RU2451523C2 (ru) * | 2005-12-14 | 2012-05-27 | Цитос Биотехнологи Аг | Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности |
| CA2798323A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| HUP1100470A2 (en) | 2011-08-30 | 2013-03-28 | Mezoegazdasagi Biotechnologiai Kutatokoezpont | Nanoparticle-based veterinary vaccine |
| CN102943087A (zh) * | 2012-11-26 | 2013-02-27 | 中国农业科学院上海兽医研究所 | 兔出血症病毒新型亚单位疫苗及其制备方法 |
| US10050902B2 (en) | 2013-10-28 | 2018-08-14 | Hitachi, Ltd. | Methods and apparatus for de-duplication and host based QoS in tiered storage system |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| HK1255206A1 (zh) * | 2015-09-08 | 2019-08-09 | 苏黎世大学 | 抗猫过敏的组合物 |
| CA2994353A1 (en) * | 2015-09-08 | 2017-03-16 | Universitat Zurich | Treatment of insect bite hypersensitivity |
-
2015
- 2015-10-19 MA MA040824A patent/MA40824A/fr unknown
- 2015-10-20 AU AU2015335027A patent/AU2015335027B2/en active Active
- 2015-10-20 WO PCT/EP2015/074269 patent/WO2016062720A1/en not_active Ceased
- 2015-10-20 RU RU2017111266A patent/RU2706970C2/ru active
- 2015-10-20 MY MYPI2017701368A patent/MY187462A/en unknown
- 2015-10-20 TN TN2017000133A patent/TN2017000133A1/en unknown
- 2015-10-20 SG SG11201703083QA patent/SG11201703083QA/en unknown
- 2015-10-20 CN CN202210351341.8A patent/CN114685626B/zh active Active
- 2015-10-20 KR KR1020177013820A patent/KR102775741B1/ko active Active
- 2015-10-20 JP JP2017522532A patent/JP6942313B2/ja active Active
- 2015-10-20 EP EP15781949.1A patent/EP3209326A1/en active Pending
- 2015-10-20 US US15/520,676 patent/US10532107B2/en active Active
- 2015-10-20 KR KR1020257006196A patent/KR20250034187A/ko active Pending
- 2015-10-20 NZ NZ731205A patent/NZ731205A/en unknown
- 2015-10-20 MX MX2017005242A patent/MX387985B/es unknown
- 2015-10-20 CA CA2963709A patent/CA2963709A1/en active Pending
- 2015-10-20 SG SG10201903538YA patent/SG10201903538YA/en unknown
- 2015-10-20 CN CN201580064884.XA patent/CN108064276B/zh active Active
- 2015-10-20 PE PE2017000737A patent/PE20171133A1/es unknown
-
2017
- 2017-04-03 IL IL251532A patent/IL251532B/en active IP Right Grant
- 2017-04-20 CL CL2017000987A patent/CL2017000987A1/es unknown
- 2017-04-20 PH PH12017500727A patent/PH12017500727A1/en unknown
- 2017-04-27 CO CONC2017/0004119A patent/CO2017004119A2/es unknown
-
2019
- 2019-11-26 US US16/696,161 patent/US11324836B2/en active Active
-
2022
- 2022-04-06 US US17/714,307 patent/US20220305131A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538672A5 (cg-RX-API-DMAC7.html) | ||
| RU2017111266A (ru) | Модифицированные вирусоподобные частицы вируса мозаики огурца | |
| Balke et al. | Recent advances in the use of plant virus-like particles as vaccines | |
| RU2486206C2 (ru) | Гипоаллергенный слитый белок, молекула нуклеиновой кислоты, кодирующая его, вектор экспрессии, клетка-хозяин, вакцинная композиция и его применение | |
| JP2014530010A5 (cg-RX-API-DMAC7.html) | ||
| Deng et al. | Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge | |
| JP2015501840A5 (cg-RX-API-DMAC7.html) | ||
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| JP2010516290A5 (cg-RX-API-DMAC7.html) | ||
| Shim et al. | Sublingual delivery of vaccines for the induction of mucosal immunity | |
| JP2011250797A5 (cg-RX-API-DMAC7.html) | ||
| JP2012501959A5 (cg-RX-API-DMAC7.html) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| JP2019506175A5 (cg-RX-API-DMAC7.html) | ||
| Chai et al. | DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss | |
| JP2024504566A (ja) | 核酸ワクチン | |
| TW202202169A (zh) | 預防嚴重急性呼吸症候群冠狀病毒第二型（ｓａｒｓ－ｃｏｖ－２）感染的生物可降解奈米複合物疫苗及方法 | |
| JP2016511747A5 (cg-RX-API-DMAC7.html) | ||
| JP2010506926A5 (cg-RX-API-DMAC7.html) | ||
| Nagpal et al. | Current clinical status of new COVID-19 vaccines and immunotherapy | |
| JP2015529677A5 (cg-RX-API-DMAC7.html) | ||
| Nie et al. | Self-adjuvant multiepitope nanovaccine based on ferritin induced long-lasting and effective mucosal immunity against H3N2 and H1N1 viruses in mice | |
| Ramirez et al. | Co‐Delivery of Multiple Toll‐Like Receptor Agonists and Avian Influenza Hemagglutinin on Protein Nanoparticles Enhances Vaccine Immunogenicity and Efficacy | |
| Ding et al. | A Universal Influenza Nanovaccine for “Mixing Vessel” Hosts Confers Potential Ability to Block Cross‐Species Transmission | |
| Zhang et al. | Multi-COBRA hemagglutinin formulated with cGAMP microparticles elicits protective immune responses against influenza viruses |